As marijuana laws continue to evolve, employers are facing increasing pressure to modernize their drug testing policies to stay compliant with changing regulations. The first cannabis bills of 2026 are sending signals to employers that it’s time to adapt.
In Mississippi, lawmakers are advancing two separate bills that split legalization from drug scheduling. One bill legalizes possession for adults 21 and over, establishes a licensing and tax structure, and builds a regulatory regime for cultivation, manufacturing, and retail sales. The other bill removes marijuana from Schedule I under Mississippi law and adjusts penalties across the controlled substances code. This policy-versus-practice split creates exposure for employers, as rescheduling does not require accommodation or restrict drug testing, but it does change how marijuana is legally viewed.
In Hawaii, lawmakers are pursuing two parallel paths to establish a full adult-use cannabis framework, including a Hawaii Cannabis and Hemp Office, licensing, taxation, and unified regulation of medical, adult-use, and hemp products. They are also introducing constitutional amendment bills that would ask voters to decide whether to legalize adult-use cannabis. This dual-track approach is a signal to employers that Hawaii is no longer debating whether legalization should happen, but rather how.
In Nebraska, lawmakers are implementing medical cannabis after voters forced the issue. The bill amends the Nebraska Medical Cannabis Patient Protection Act and the Medical Cannabis Regulation Act, harmonizes tax and enforcement provisions, and clarifies how cannabis will be treated across state codes. Importantly for employers, it preserves employer discretion, allowing them to maintain drug-free workplaces and tie workplace misconduct involving cannabis to unemployment disqualification.
At the federal level, Congress is pressing pause on a new hemp definition that would have reshaped THC compliance nationwide. This delay leaves employers in a gray area, where lawful hemp use can lead to positive drug tests.
The takeaway for employers is that waiting for clarity is the risk. None of these bills require employers to accommodate cannabis use at work or ban drug testing outright, but the momentum towards normalization is clear. Employers should modernize their policies by revisiting safety-sensitive definitions, clarifying impairment standards, training managers on accommodation conversations, and ensuring drug testing programs align with current law and business necessity.
The early marijuana filings of 2026 are not the end of the story, but rather a reminder that the compliance playbook is still being rewritten, and employers must be proactive to stay ahead of the changing landscape.
